StockWatch
·
Biotechnology: Biological Products (No Diagnostic Substances)
Loan & DebtJun 24, 2026, 09:00 PM

Mesoblast Secures $50M Debt Facility, Retires High-Cost Debt

AI Summary

Mesoblast Limited announced it drew down US$50 million from a new five-year debt facility provided by existing shareholder and director Dr. Gregory George. This new facility, with an 8.00% fixed interest rate and a five-year interest-only period, will be used to retire higher-cost debt from NovaQuest Capital Management LLC, optimizing the company's capital structure. Mesoblast reported US$122 million in cash as of March 30, 2026, and states it is well-funded for commercial operations and growth.

Key Highlights

  • Mesoblast drew down US$50 million from a new five-year debt facility.
  • The company had US$122 million cash at March 30, 2026.
  • The new credit facility has a fixed interest rate of 8.00% per annum.
  • It includes a five-year interest-only period from the initial draw.
  • The facility is secured solely with the Temcell royalty and can be repaid early without fees.